We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02066571
Recruitment Status : Unknown
Verified November 2016 by Peter LeWitt MD, Henry Ford Health System.
Recruitment status was:  Enrolling by invitation
First Posted : February 19, 2014
Last Update Posted : November 3, 2016
Sponsor:
Information provided by (Responsible Party):
Peter LeWitt MD, Henry Ford Health System

Brief Summary:

Since droxidopa has been approved in Japan for treating freezing of gait in Parkinson's disease patients, this is to confirm and further investigate the safety and efficacy using a similar dose. The possible beneficial effects on cognition in mildly cognitively impaired Parkinson's disease patients will also be tested, since this problem in Parkinson's disease may be associated with decreased brain synthesis of norepinephrine (a neurotransmitter associated with multiple brain functions).

During this 11 week study, droxidopa will be slowly titrated up to 600 mg daily. Walking and freezing of gait will be evaluated and rated. Cognitive functions will be evaluated by a computer-based program.


Condition or disease Intervention/treatment Phase
Parkinson's Disease Freezing of Gait Cognitive Ability, General Drug: Droxidopa Drug: sugar pill Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II, Double-Blind, Placebo-Controlled, Crossover Study to Assess Clinical Benefit and Safety of Droxidopa in the Treatment of Parkinson's Disease
Study Start Date : March 2015
Estimated Primary Completion Date : April 2017
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Droxidopa

Arm Intervention/treatment
droxidopa, then sugar pill
Droxidopa will be titrated over a 2-week period up to 300 mg twice daily (600 mg total daily dose). Subjects will be titrated to highest tolerated dose and will continue on that dose for two weeks. Then, the subject will start sugar pills.
Drug: Droxidopa
Droxidopa will be supplied in 100 and 200 mg pill sizes. The proposed dosing is 100mg twice daily at baseline, then titrate to 200 mg twice daily at day 7 and then titrate to 300mg twice daily at day 14. Subjects will stay on the 600mg daily for 2 weeks. Total exposure 28 days of study drug.

Drug: sugar pill
Sugar pill or placebo will be supplied in pill sizes matched to droxidopa formulation. The study titration will be the same. Sugar pills will be used for 5 weeks during the study.
Other Name: placebo

sugar pill, then droxidopa
Subject will be be on sugar pill for 5 weeks (4 weeks of placebo treatment and one week of wash-out or sugar pills). Then, droxidopa will be titrated over 2 week period up to 300 mg twice daily (600 mg total daily dose). Subjects will be titrated to highest tolerated dose and will continue on that dose for two weeks.
Drug: Droxidopa
Droxidopa will be supplied in 100 and 200 mg pill sizes. The proposed dosing is 100mg twice daily at baseline, then titrate to 200 mg twice daily at day 7 and then titrate to 300mg twice daily at day 14. Subjects will stay on the 600mg daily for 2 weeks. Total exposure 28 days of study drug.

Drug: sugar pill
Sugar pill or placebo will be supplied in pill sizes matched to droxidopa formulation. The study titration will be the same. Sugar pills will be used for 5 weeks during the study.
Other Name: placebo




Primary Outcome Measures :
  1. Change from baseline in freezing of gait symptoms using Freezing of Gait Questionnaire [ Time Frame: 4 weeks ]
    Evaluate the effect of droxidopa on freezing of gait symptoms using the Freezing of Gait Questionnaire completed by patients. All measures will be performed at baseline and after two and four weeks of study medication.

  2. Change from baseline in cognitive testing [ Time Frame: 4 weeks ]
    Battery of cognitive testing is performed. All measures will be performed at baseline and after two and four weeks of study medication.


Secondary Outcome Measures :
  1. Change in measurement of freezing of gait [ Time Frame: 4 weeks ]
    Videotaped evaluations quantifying the number of episodes of freezing of gait and their severity will be rated using the Observed Freezing of Gait scale. The Timed Up and Go test will evaluate the effect of droxidopa on PD symptoms. The effect of droxidopa treatment on gait features of stride, swing time variability, and gait asymmetry will be analyzed. All measures will be performed at baseline and after two and four weeks of study medication.

  2. Change in the incidence of falls [ Time Frame: 4 weeks ]

    Videotaped evaluations quantifying the number of fall episodes will be rated using the Observed Freezing of Gait scale. The Timed Up and Go test will evaluate the effect of droxidopa on PD symptoms and freezing of gait. The effect of droxidopa on falls will be analyzed using the GaitRite system.

    All measures will be performed at baseline and after two and four weeks of study medication.


  3. Change in signs and symptoms of Parkinson's disease [ Time Frame: 4 weeks ]
    The UPDRS (Unified Parkinson's Disease Rating Scale) will be performed at baseline and after 2 and 4 weeks on study drug for each arm.

  4. Number of participants with serious and non-serious adverse events [ Time Frame: up to 11 weeks ]
    Safety of droxidopa will be evaluated based on the occurrence of treatment emergent adverse events with specific evaluation of blood pressure, heart rate , ECG, suicidality, and laboratory findings across the study



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Provide written informed consent to participate in the study
  • Diagnosed with probable levodopa-responsive idiopathic PD (meeting United Kingdom PD Brain Bank diagnostic criteria), and receiving levodopa therapy for this disorder. Other PD medications can also be used.
  • Must have AT LEAST ONE of below two criteria:

    1. At least 3 months incidence of typical freezing of gait symptoms, occurring while levodopa is otherwise providing an "on" mobility state (including at least one of the following Freezing of Gait patterns: start hesitancy, freezing at making turns or when passing through a doorway, spontaneous freezing during continued walking, or Freezing of Gait related to a simultaneous mental or physical activity) OR
    2. Have a screening score between 22 and 26 (inclusive) on the Montreal Cognitive Assessment

Exclusion Criteria:

  • Taking direct acting vasoconstriction agent (i.e. ephedrine or midodrine). Subjects taking vasoconstrictor agents such as ephedrine or midodrine must stop taking these drugs at least 2 days or 5 half-lives (whichever is longer) prior to their baseline visit
  • Taking anti-hypertensive medication for the treatment of hypertension. Anti-hypertensive medication taken at night to prevent supine hypertension will be allowed
  • Changing dose or frequency of PD medication within 2 weeks of baseline
  • Use of cognitive-enhancing medications (donepezil, galantamine, rivastigmine, tacrine, or memantine), catechol-O-methyltransferase inhibitors (tolcapone or entacapone), anticholinergic drugs, or antipsychotic drugs (including quetiapine or clozapine).
  • Known or suspected alcohol or substance abuse within 1 year (e.g. DSM-IV definition of alcoholism)
  • Past or current history of chronic severe hypertension (with repeated findings of BP 150/90 mmHg in the supine or standing position)
  • Symptomatic coronary artery disease, severe congestive heart failure (NYHA Class 3 or 4)
  • Unable to remain off any effective Freezing of Gait medications for 12 hrs prior to Evaluation visits)
  • Women who are pregnant, lactating, or plan to become pregnant during the course of this study
  • Women of child bearing potential who are not using two methods of contraception (at least one barrier, i.e. condom) with their partner.
  • Male subjects who are sexually active with a woman of child bearing potential and not using two methods of contraception (at least one barrier, for example, condom)
  • A history of closed angle glaucoma;
  • Active (in the last 6 months) atrial fibrillation or, in the investigator's opinion, any other significant cardiac arrhythmia that should preclude the subject from this trial
  • History of myocardial infarction or unstable angina
  • Congestive heart failure (NYHA Class 3 or 4)
  • Diabetes insipidus, insulin-dependent diabetes mellitus, or diabetic neuropathy
  • In the investigator's opinion, any other significant systemic illness
  • Known or suspected malignancy (other than basal cell carcinoma)
  • Known gastrointestinal illness or other gastrointestinal disorder that may, in the investigator's opinion, affect the absorption of study drug
  • Any major surgical procedure within 30 days of the baseline visit
  • Currently receiving any investigational drug or have received an investigational drug within 30 days of the baseline visit
  • In the investigator's opinion, clinically significant abnormalities on clinical examination or laboratory testing that should preclude the subject from this trial.
  • Findings from suicidality screening that are compatible with risk for suicide

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02066571


Locations
Layout table for location information
United States, Illinois
Rush University Medical Center
Chicago, Illinois, United States, 60612
United States, Michigan
Henry Ford Hospital, West Bloomfield
West Bloomfield, Michigan, United States, 48322
Sponsors and Collaborators
Henry Ford Health System
Investigators
Layout table for investigator information
Principal Investigator: Peter LeWitt, M.D. Henry Ford Health System
Layout table for additonal information
Responsible Party: Peter LeWitt MD, M.D., Henry Ford Health System
ClinicalTrials.gov Identifier: NCT02066571    
Other Study ID Numbers: LeWitt01
IND 119340 ( Other Identifier: FDA )
First Posted: February 19, 2014    Key Record Dates
Last Update Posted: November 3, 2016
Last Verified: November 2016
Keywords provided by Peter LeWitt MD, Henry Ford Health System:
Parkinson's disease
Freezing of gait
Gait
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Synucleinopathies
Neurodegenerative Diseases
Droxidopa
Antiparkinson Agents
Anti-Dyskinesia Agents